Company news
Surrozen, Inc. (NASDAQ:SRZN) news
Surrozen, Inc. news releases on 6ix. Latest, Oct 2, 2026: Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic…
Press releases & updates
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
October 1, 2026
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
October 2, 2026
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
September 8, 2026
Surrozen : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
August 6, 2026
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 22, 2026
Surrozen to Present at Upcoming Healthcare Investor Conference
February 5, 2026
Surrozen to Present at Upcoming Healthcare Investor Conferences
November 25, 2025
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 12, 2025
Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
November 7, 2025
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2025
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
August 8, 2025
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
May 14, 2025
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
May 9, 2025
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
March 31, 2025
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
March 24, 2025
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
March 23, 2025
Surrozen Provides Third Quarter 2024 Financial Results and Business Update
November 5, 2024
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
November 3, 2024
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
September 23, 2024
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
August 11, 2024
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
June 9, 2024
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
June 3, 2024
Surrozen Provides First Quarter 2024 Financial Results and Business Update
May 7, 2024
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
March 31, 2024
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
March 31, 2024
Surrozen Provides Corporate Update on Clinical Programs
January 17, 2024
Surrozen Provides Third Quarter 2023 Financial Results
November 7, 2023
Surrozen Provides Second Quarter 2023 Financial Results
August 8, 2023
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
May 9, 2023
Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt
April 4, 2023
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress
March 21, 2023
Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023
March 19, 2023
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 13, 2022
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases
October 5, 2022
Surrozen Reports Second Quarter 2022 Financial Results
August 10, 2022
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis
June 12, 2022
Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
May 23, 2022
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
May 17, 2022
Surrozen Reports First Quarter 2022 Financial Results
May 10, 2022
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 1, 2022
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
March 23, 2022
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline
January 9, 2022
Surrozen Reports Third Quarter 2021 Financial Results
November 14, 2021
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
November 14, 2021
Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources
September 22, 2021